Background/Purpose: The efficacy of apremilast vs placebo for the treatment of oligoarticular PsA of ≤2 years duration is being investigated in the FOREMOST trial (NCT03747939). There is a paucity of real-world data characterizing patients (pts) with oligoarticular PsA. The Corrona PsA/SpA Registry, a prospective, observational cohort study, collects real-world data on US pts with PsA. The current analysis compared characteristics of pts with early oligoarticular PsA in the Corrona PsA/SpA Registry who would generally meet eligibility criteria for FOREMOST with the remainder of the PsA registry population.

Methods: Pts ≥18 years of age diagnosed with PsA who enrolled in the registry from March 2013 to February 2020 were included in the analysis. The FOREMOST-eligible group consisted of pts diagnosed with PsA within 2 years prior to enrollment who were naive to biologic DMARDs or targeted systemic DMARDs (apremilast or tofacitinib), had a history of ≤1 prior conventional synthetic DMARD (csDMARD [methotrexate, hydroxychloroquine, sulfasalazine, leflunomide]), and had swollen joint counts (0-66) of 2 to 4 and tender joint counts (0-68) of 2 to 4. The remainder of the PsA registry population included pts with PsA who did not meet these criteria. Data on patient demographics, clinical characteristics, treatment, disease activity, and patient-reported outcomes at enrollment are summarized descriptively.

Results: Of the 3,556 pts with PsA enrolled in the registry, 109 (3.1%) were included in the FOREMOST-eligible group and 3,447 (96.9%) comprised the remainder of the PsA registry population. Baseline characteristics among the 2 populations were generally similar, with slightly younger pts and proportionally more women in the FOREMOST-eligible group than in the remainder of the PsA registry population (Table 1). FOREMOST-eligible pts had shorter duration of PsA and shorter time to PsA diagnosis than the remainder of the PsA registry population (Table 1). Prior and current csDMARD use in the FOREMOST-eligible pts was lower than in the remainder of the PsA registry population (Table 1). FOREMOST-eligible pts had higher mean scores for patient-reported pain visual analog scale (VAS) and the Physician’s Global Assessment (PhGA) of PsA VAS, in the context of comparable overall mean DAPSA, cDAPSA, PsA Disease Activity Score (PASDAS), and Routine Assessment of Patient Index Data 3 (RAPID3) scores (Table 2). Compared with the remainder of the PsA registry population, FOREMOST-eligible pts were less likely to be in minimal disease activity and more likely to have moderate disease activity based on the cDAPSA, DAPSA, and PASDAS (Table 2). Prevalence of dactylitis was higher in the FOREMOST-eligible group, whereas prevalence of enthesitis was higher in the remainder of the PsA registry population.

Conclusion: In the Corrona PsA/SpA Registry, pts with early oligoarticular PsA based on approximating FOREMOST trial criteria were the minority of the enrolled pts. Descriptive statistics of this small but understudied population indicated a higher burden of patient-reported pain and PhGA of PsA compared with the remainder of the PsA registry population, suggesting there is unmet need in this population.

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-of-patients-with-early-oligoarticular-psoriatic-arthritis-in-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/